Additionally, influencing the PD-L1 expression, the KRAS (G13D) mutation in CRC cell lines reduced the communication of MHC class I molecules, which is detrimental to the immunogenicity of tumor cells [103]. The gene discussed is KRAS; the disease is neoplasm.